Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19
Filter: PRESS RELEASES IN THE NEWS EVENTS
Sentien to Present SBI-101 Clinical Data in AKI at 2020 American Society of Gene & Cell Therapy Annual Meeting that Supports Expansion to COVID-19
Sentien’s R&D team will present platform development and clinical data at the American Society of Gene & Cell Therapy Annual Meeting during virtual poster sessions.
Sentien’s SBI-101 clinical data in AKI patients shows immunomodulatory effects consistent with our therapeutic hypothesis and also applicable to COVID-19 patients.
Clinical Evidence for Immune Reprogramming with Extracorporeal Mesenchymal Stromal Cell Therapy
Ex-Vivo Cell Therapy Platform for Immune Reprogramming in Autoimmunity
